Penile Filler Complications: Recognition, Clinical Decision-Making and Management Principles

Complication management is not a secondary skill in penile filler practice. It is part of the original treatment plan.

For physicians, the relevant question is not simply how to perform hyaluronic acid (HA) penile girth enhancement. The more complete questions are:

Which patient should be treated? What could go wrong? How can early deviation from an expected course be recognised? What information is needed when a problem appears? When is observation reasonable, when is reassessment needed, and when should care be escalated?

This is the clinical layer that separates a procedural demonstration from a complete educational programme.

Current literature supports a relatively favourable observed complication profile for HA compared with some permanent augmentation materials, but that does not make HA risk-free. A 2026 systematic review and meta-analysis included 23 studies and 2,620 participants. Across all included penile-augmentation approaches, the pooled complication rate was 14.9%. HA had the numerically lowest pooled estimate at 9.0%, but comparisons between materials were indirect and there were no direct head-to-head randomised trials between the major materials.

Those figures should therefore inform context, not become a shortcut for clinical judgement.

The central educational principle is:

Complication management starts before the complication occurs.

Why complication management should be taught before technique

A complication rarely arrives with a label.

A patient may report swelling, pain, colour change, asymmetry, a palpable lump, discharge or simply that “something does not look right.” The clinical task is not to jump directly to correction. It is to determine what the finding represents, how urgent it may be, what material is present and what information is still missing.

That process depends on decisions made before treatment:

• patient selection;
• anatomical assessment;
• product identification;
• documentation;
• realistic volume planning;
• informed consent;
• follow-up design;
• access to reassessment.

If those foundations are weak, complication management becomes more difficult.

This is why Apex teaches patient selection, anatomy, planning, safety, follow-up and complication reasoning as one connected process rather than as isolated modules.

The Apex six-stage complication teaching framework

The following framework is used as an educational decision model, not as a validated clinical scoring system:

Prevent → Recognize → Classify → Trace → Decide → Follow

It is designed to help physicians structure thinking when an expected post-treatment course begins to deviate.

1. Prevent

Prevention begins with deciding whether treatment should proceed at all.

Relevant pre-procedure considerations may include:

• active infection or inflammation;
• genital skin and soft-tissue findings;
• previous filler or unknown injected material;
• previous genital surgery;
• scarring or anatomical distortion;
• conditions that may affect bleeding or healing;
• medicines and relevant medical history;
• patient expectations;
• body-image or dysmorphic concerns where clinically relevant.

Prevention also includes product traceability.

“HA filler” is not complete documentation. The exact product, manufacturer and batch/lot should be retrievable according to local requirements and the clinical record system.

For elective treatment, the option to defer or decline treatment is itself part of safety.

2. Recognize

The first post-treatment challenge is distinguishing expected early recovery from concerning progression.

Some oedema, bruising, tenderness and temporary contour variation may occur after injection. Those findings are not automatically complications.

Concern increases when the pattern changes:

• symptoms are more severe than expected;
• pain is increasing rather than settling;
• swelling is rapidly progressive;
• colour is changing;
• erythema/warmth is worsening;
• discharge or systemic illness appears;
• tissue findings are evolving rather than stabilising;
• the patient develops chest pain, dyspnoea, collapse or loss of consciousness.

The educational objective is not to label every early finding as pathology. It is to recognise when the trajectory no longer fits an uncomplicated recovery.

3. Classify

Before attempting correction, the problem should be placed into a clinically useful category.

A practical teaching classification is:

A. Expected or self-limited early changes

Examples may include uncomplicated oedema, bruising, tenderness or temporary minor contour variation.

B. Structural or contour problems

Examples may include persistent asymmetry, palpable nodularity, over- or under-correction, migration or redistribution.

C. Inflammatory or infectious concerns

Progressive erythema, warmth, increasing pain, discharge, systemic symptoms or abscess concern require a different decision pathway from uncomplicated contour issues.

D. Tissue-perfusion or vascular concern

Progressive severe pain, concerning colour change, blistering or tissue compromise require urgent assessment.

E. Systemic emergency

Chest pain, dyspnoea, collapse or loss of consciousness should be treated as medical emergencies rather than routine filler follow-up.

This classification is intentionally broad. It helps determine urgency before a specific corrective strategy is considered.

4. Trace

When a complication is assessed, treatment history becomes diagnostic information.

The physician should try to establish:

• what material was injected;
• exact product if known;
• manufacturer and batch/lot if available;
• when it was injected;
• approximate amount used;
• whether treatment was staged;
• whether other fillers or foreign materials were previously present;
• whether there was previous genital surgery;
• when symptoms began;
• how symptoms have progressed;
• whether another intervention has already been attempted.

This step becomes especially important in referral cases and medical tourism.

A patient may present in another country with no direct access to the original treating clinician. The quality of documentation can materially change the next clinician’s ability to reason safely.

5. Decide

Only after recognition, classification and history reconstruction should the next level of action be determined.

For teaching purposes, the decision can be framed at four levels:

Level 1 — Planned review

The course appears consistent with expected recovery and there are no concerning features. Clear communication and planned reassessment remain important.

Level 2 — Prompt clinical reassessment

A persistent structural problem, nodularity, asymmetry, migration or another non-emergency finding requires examination before any correction is chosen.

Level 3 — Urgent local assessment / escalation

Progressive pain, inflammatory/infectious features, concerning colour change, tissue compromise or rapidly evolving findings should not be managed as routine cosmetic follow-up.

Level 4 — Emergency care

Systemic emergency symptoms require emergency medical evaluation.

This is not a treatment algorithm and does not replace local protocols. Its purpose is to prevent a common educational error: moving directly from “problem” to “procedure” without first deciding urgency and category.

6. Follow

Complication management does not end with the first decision.

Follow-up includes:

• documenting the finding and the reasoning;
• communicating expected next steps;
• confirming whether the trajectory is improving or worsening;
• arranging reassessment;
• coordinating specialist input where needed;
• maintaining continuity across clinicians or countries;
• reviewing what the case teaches about future patient selection and planning.

A complication should therefore generate not only a management decision but also a learning loop.

Common complication groups in HA penile filler practice

Oedema and bruising: expected recovery versus concerning progression

Early swelling and bruising can occur after injection.

The clinically important skill is not eliminating all post-procedure swelling. It is identifying a pattern that no longer behaves like expected recovery.

Questions include:

• Is the swelling stable, improving or rapidly increasing?
• Is pain proportionate and improving?
• Is there progressive erythema or warmth?
• Is there significant colour change?
• Are systemic symptoms present?
• Is the patient able to urinate normally?
• Is the tissue appearance stable?

Trajectory matters.

Asymmetry and contour irregularity

Not every irregularity should trigger immediate correction.

Early swelling can distort contour. Conversely, persistent asymmetry may reflect filler distribution, pre-existing anatomy, over- or under-correction or migration.

The educational principle is:

Assess the cause before selecting the correction.

Aesthetic dissatisfaction is not a diagnosis.

Timing, examination and material history matter.

Nodules and palpable irregularities

A palpable nodule can represent different processes.

The differential may include material distribution, local product accumulation, inflammatory reaction, infection-related change or other tissue response.

This is one reason why “nodule = hyaluronidase” is an unsafe oversimplification.

Before any corrective intervention, the clinician needs to understand:

• timing;
• tenderness;
• inflammatory signs;
• progression;
• relationship to previous filler;
• whether the material is confirmed HA.

Migration and redistribution

Migration is described in the literature after penile filler.

Assessment should consider the original treatment area, current location of the material, timing, previous procedures and whether the problem is primarily cosmetic or associated with inflammation, pain or tissue compromise.

Again, the first step is classification, not automatic correction.

Suspected infection

Infection requires a different mindset from uncomplicated contour problems.

Increasing pain, progressive erythema/warmth, purulent discharge, systemic symptoms or abscess concern should prompt clinical assessment rather than cosmetic adjustment.

Public educational content should not reduce this to an antibiotic recipe. The key learning objective is recognition, urgency and escalation.

Detailed drug choices, doses and emergency protocols belong in controlled professional education and local clinical protocols.

Foreskin oedema and phimosis-related problems

The 2025 urological review of penile enhancement complications includes phimosis among recognised HA-related problems.

Circumcision status and foreskin anatomy therefore matter both before treatment and when post-treatment swelling is evaluated.

The key educational lesson is that a local genital complication can alter urinary comfort, hygiene and tissue pressure and may require prompt reassessment.

Tissue-perfusion and skin warning signs

Progressive severe pain, concerning colour change, blistering or tissue breakdown should not be treated as routine dissatisfaction.

These findings change the urgency level.

The public professional article should make that distinction explicit while keeping detailed emergency-treatment protocols inside controlled physician training.

Systemic complications and pulmonary embolism

Rare severe systemic events have been reported.

A 2025 forensic report described fatal non-thrombotic pulmonary embolism after penile enlargement with an HA-based injectable material. A separate 2026 case in Thailand was linked by a UK coroner to a fatal pulmonary embolic event after penile filler treatment.

These cases do not establish the population incidence of fatal embolism.

Nor does the approximately 40 mL reported in the Thailand case establish a universal unsafe dose.

Their educational value is different:

They demonstrate why systemic symptoms after an injectable genital procedure cannot be dismissed simply because the treatment was “non-surgical.”

Chest pain, dyspnoea, collapse or loss of consciousness require emergency medical evaluation.

Hyaluronidase: a decision, not a reflex

Hyaluronidase is an important tool when the material is confirmed HA and the clinical problem makes dissolution relevant.

But it should not be presented as the automatic answer to every adverse finding.

The decision depends on questions such as:

• Is the material definitely HA?
• What is the actual complication?
• Is there infection?
• Is the issue primarily contour-related?
• Is there a more urgent tissue or systemic concern?
• What has already been done?
• What is the timing of the problem?

The teaching principle is simple:

Diagnosis and urgency come before dissolution.

The public article deliberately does not provide dosing, injection technique or emergency-use protocols. Those details belong in controlled physician training where patient context, legal scope and supervision can be addressed appropriately.

Product traceability is part of complication management

Traceability is sometimes treated as administrative detail. It is not.

When a complication occurs, knowing the product, batch and treatment history can affect clinical reasoning.

This is especially important in patients who have:

• been treated abroad;
• received filler from more than one clinician;
• received multiple products;
• undergone prior genital surgery;
• received a material they cannot identify.

A patient presenting with “penile filler complication” is not one diagnosis.

The material history matters.

Documentation should support the next clinical decision

Good documentation should help the clinician answer:

• What was the baseline anatomy?
• What material was used?
• What was the treatment plan?
• What was the early post-treatment course?
• When did the abnormal finding begin?
• What has changed since?
• What has already been attempted?
• What follow-up has occurred?

In international care, documentation should also be usable by a clinician who did not perform the original treatment.

This is a continuity-of-care issue, not merely a paperwork issue.

Communication is part of complication management

Patients need to know what is expected, what is not expected and how to access reassessment.

A strong follow-up system reduces two opposite risks:

1. unnecessary panic over normal early recovery;
2. dangerous delay when a concerning pattern is developing.

Clear communication should therefore be designed before treatment.

Medical tourism raises the value of follow-up planning

International patients may leave the treating country before all early changes have resolved.

The relevant questions should be addressed in advance:

• How long will the patient remain locally?
• When is the first review?
• What records will the patient receive?
• How can another clinician identify the product?
• Who can be contacted after return home?
• What symptoms require local urgent or emergency care rather than waiting for the treating clinic?

A short procedure does not create a short biological follow-up period.

What recent adverse events should change in training

Rare adverse events should not be turned into fear marketing.

They should change the quality of education.

For Apex, the most important learning points are:

1. Complication management begins with patient selection.
2. Expected recovery must be distinguished from concerning progression.
3. The actual problem must be classified before correction is chosen.
4. Material identity and treatment history are clinical information.
5. Hyaluronidase is a decision, not a reflex.
6. Urgency and referral are part of competence.
7. Follow-up and documentation are part of the original treatment plan.

The Apex teaching position

At Apex Andrology Academy, penile filler education is not built around a single injection technique.

The programme connects:

patient selection → anatomy → planning → clinical execution → follow-up → complication recognition → management decisions → referral when needed

The goal is not to teach a recipe.

The goal is to teach a repeatable clinical decision process.

That is why complication management is not placed at the end of the curriculum as an afterthought. It is one of the central ways the curriculum is organised.

Clinical perspective — Cem Özlük, MD

When a complication is referred to me, my first question is not, “How do we correct the appearance?”

I first want to understand:

What was injected, when was it injected, what is happening now, and how urgent is it?

If the material is unknown, that uncertainty itself becomes part of the problem.

If the patient has increasing pain, changing tissue colour, inflammatory findings or systemic symptoms, the priority is not cosmetic correction.

If the problem is structural and non-urgent, timing and cause still matter before intervention.

This is the core principle I want physicians to take from complication training:

Do not treat the appearance before you understand the problem.

Conclusion

Complication competence in penile filler practice is broader than knowing one corrective procedure.

It requires the physician to:

prevent → recognize → classify → trace → decide → follow

The safest educational model is therefore not “how to inject” followed by a short complications section.

It is a clinical framework in which complication preparedness influences patient selection, planning, documentation and follow-up from the beginning.

For HA penile girth enhancement, that is where technical education becomes clinical education.

References

1. European Association of Urology. Sexual and Reproductive Health Guidelines — Penile Size Abnormalities and Dysmorphophobia.
2. Fonseca TDF, Querobino SM. Penile augmentation procedures: a systematic review and meta-analysis of techniques, materials, and safety outcomes. Sex Health. 2026. PMID 42402428. DOI 10.1071/SH26112.
3. Pignanelli C, et al. Complications and management of penile enhancement procedures. Transl Androl Urol. 2025. PMID 41230130. DOI 10.21037/tau-23-519.
4. Chung E, et al. Penile augmentation and cosmetic surgery: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024). PMID 41344863.
5. Trost L, et al. Cosmetic penile enhancement procedures: an SMSNA position statement. J Sex Med. 2024. PMID 38654638.
6. Shigeev SV, et al. Fatal non-thrombotic pulmonary embolism in penis enlargement with injections of hyaluronic acid-based drugs. 2025. PMID 40017089. DOI 10.17116/sudmed20256801159.
7. Filler-induced non-thrombotic pulmonary embolism after genital aesthetic injection. PMID 35969584.
8. The Nation Thailand. Influencer’s death linked to filler injections in Thailand. 6 Sep 2026.
9. Euronews / AFP. Thailand investigates after British influencer dies following penis enlargement operation. 9 Sep 2026.